MedTrace Logo

Performance and Safety of the Globe® Mapping and Ablation System With the GPS™ Module for the Treatment of Atrial Fibrillation

NCT04486924 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2023-02-10

No results posted yet for this study

Summary

This study will evaluate the safety and acute performance of the Globe® Mapping and Ablation System with the GPS™ Module intended to conduct electroanatomic mapping and ablation treatment of subjects with atrial fibrillation (AF).

Conditions

Interventions

DEVICE

Globe Mapping and Ablation System

Prospective, non-randomized, open-label clinical study.

Sponsors & Collaborators

  • Kardium Inc.

    lead INDUSTRY

Principal Investigators

  • Southlake Regional Health Centre · 596 Davis Dr, Newmarket ON L3Y 2P9, Canada

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-05
Primary Completion
2022-08-30
Completion
2022-08-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04486924 on ClinicalTrials.gov